Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care

Cytotherapy

Volumn 16, Issue 2, 2014, Pages 234-244

  Bapsy, Poonamalle Parthasarathy ^a   Sharan, Bandana ^b   Kumar, Chaitanya ^b   Das, Rajeev Patrick ^b   Rangarajan, Bharath ^c   Jain, Minish ^d   Suresh Attili, Venkata Sathya ^e   Subramanian, Sundaram ^f   Aggarwal, Shyam ^g   Srivastava, Mala ^h   Vaid, Ashok ^d  

^a Apollo Hospitals   (India)

^b Premas Biotech Pvt Ltd   (India)

^c Narayan Hrudayalaya Hospital   (India)

^d Ruby Hall Clinic ^*  (India)

^e APOLLO HOSPITAL   (India)

^f VS Hospital   (India)

^g SIR GANGA RAM HOSPITAL   (India)

^h Nextvel Consulting LLP   (India)

Author keywords

Cancer immunotherapy; Dendritic cells; Monocytes

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CELL PROTEIN; DC205 PROTEIN; DC209 PROTEIN; GAMMA INTERFERON; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LEUKAPHERESIS; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; SURVIVAL TIME; TUMOR BIOPSY;

CANCER IMMUNOTHERAPY; DENDRITIC CELLS; MONOCYTES;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA; CELL DIFFERENTIATION; CELL EXTRACTS; CELLS, CULTURED; COLONIC NEOPLASMS; CYTOKINES; DENDRITIC CELLS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; INDIA; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84892460559     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.11.013     Document Type: Article

References (40)

1. Liotta L.A., Kohn E. Cancer invasion and metastases. JAMA 1990, 263:1123-1126.
2. Sporn M.B. The war on cancer. Lancet 1996, 347:1377-1381.
3. Nandakumar A. National Cancer Registry Programme, Indian Council of Medical Research: Consolidated Report of the Population-Based Cancer Registries. New Delhi: Indian Council of Medical Research 1990.
4. Steinman R.M., Cohn Z.A. Identification of a novel cell type in peripheral lymphoid organs of mice, I: morphology, quantitation, tissue distribution. JExp Med 1973, 137:1142-1162.
5. Bhargava A., Mishra D., Banerjee S., Mishra P.K. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation. Immunotherapy 2012, 4:703-718.
6. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2:52-58.
7. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4:328-332.
8. Zhang K., Gao P.F., Yu P.W., Rao Y., Zhou L.X. Study on biological characters of SGC7901 gastric cancer cell-dendritic cell fusion vaccines. World J Gastroenterol 2006, 12:3438-3441.
9. Davis I.D., Jefford M., Parente P., Cebon J. Rational approaches to human cancer immunotherapy. JLeukoc Biol 2003, 73:3-29.
10. Fricke I., Gabrilovich D.I. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006, 35:459-483.
11. Vuckovic S., Gardiner D., Field K., Chapman G.V., Khalil D., Gill D., et al. Monitoring dendritic cells in clinical practice using a new whole blood single-platform TruCOUNT assay. JImmunol Methods 2004, 284:73-87.
12. Almand B., Clark J.I., Nikitina E., van B.J., English N.R., Knight S.C., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. JImmunol 2001, 166:678-689.
13. Serafini P., De S.C., Marigo I., Cingarlini S., Dolcetti L., Gallina G., et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004, 53:64-72.
14. Kiessling R., Wasserman K., Horiguchi S., Kono K., Sjoberg J., Pisa P., et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999, 48:353-362.
15. Salih H.R., Nussler V. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?. Eur J Med Res 2001, 6:323-332.
16. Aoe T., Okamoto Y., Saito T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. JExp Med 1995, 181:1881-1886.
17. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421:852-856.
18. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300:337-339.
19. Sun J.C., Williams M.A., Bevan M.J. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 2004, 5:927-933.
20. Neller M.A., Lopez J.A., Schmidt C.W. Antigens for cancer immunotherapy. Semin Immunol 2008, 20:286-295.
21. Approval Letter. Provenge, USFood and Drugs Administration. 2010.
22. Romani N., Gruner S., Brang D., Kampgen E., Lenz A., Trockenbacher B., et al. Proliferating dendritic cell progenitors in human blood. JExp Med 1994, 180:83-93.
23. Khan J.A., Yaqin S. Successful immunological treatment of gallbladder cancer in India: case report. JZhejiang Univ Sci B 2006, 7:719-724.
24. Stift A., Friedl J., Dubsky P., Bachleitner-Hofmann T., Schueller G., Zontsich T., et al. Dendritic cell-based vaccination in solid cancer. JClin Oncol 2003, 21:135-142.
25. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
26. Richwine L. UPDATE 3: US FDA OKs Dendreon's prostate cancer vaccine. Available at: Accessed May 2, 2013. http://www.reuters.com/article/2010/04/29/dendreon-prostate-cancer-idUSN2919838820100429.
27. Wolchok J.D., Hoos A., O'Day S., Weber J.S., Hamid O., Lebbe C., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
28. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
29. D. FACIT Questionnaires. 2010. Available at: Accessed September 28, 2011. http://www.ncbi.nlm.nih.gov/pubmed/10916144.
30. Glennie M.J., Johnson P.W. Clinical trials of antibody therapy. Immunol Today 2000, 21:403-410.
31. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Linn E., Bonomi A., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. JClin Oncol 1993, 11:570-579.
32. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). May 28, 2009; September 28, 2011.
33. MedRA MSSO. MedRA FAQ. 2013. Available at: http://www.who.int/medical_devices/innovation/MedDRAintroguide_version14_0_March2011.pdf.
34. Kern F., Surel I.P., Brock C., Freistedt B., Radtke H., Scheffold A., et al. T-cell epitope mapping by flow cytometry. Nat Med 1998, 4:975-978.
35. Borowitz M, Bauer KD, Duque RE, Horton AF, Marti G, Muirhead KA, etal. Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes; Approved Guideline. National Committee for Clinical Laboratory Standards (NCCLS), USA. 1992;18:NCCLS H42-T.
36. Ahrweiler S. PhUSE Annual Conference. Brighton, 2013. April 30, 2011.
37. Figdor C.G., de Vries I.J., Lesterhuis W.J., Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat Med 2004, 10:475-480.
38. Small E.J., Fratesi P., Reese D.M., Strang G., Laus R., Peshwa M.V., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. JClin Oncol 2000, 18:3894-3903.
39. Draube A., Klein-Gonzalez N., Mattheus S., Brillant C., Hellmich M., Engert A., et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 2011, 6:e18801.
40. Holtl L., Zelle-Rieser C., Gander H., Papesh C., Ramoner R., Bartsch G., et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002, 8:3369-3376.